Show simple item record

dc.contributor.authorNeuzil, Jiri
dc.contributor.authorDyason, Jeffrey C
dc.contributor.authorFreeman, Ruth
dc.contributor.authorDong, Lan-Feng
dc.contributor.authorProchazka, Lubomir
dc.contributor.authorWang, Xiu-Fang
dc.contributor.authorScheffler, Immo
dc.contributor.authorRalph, Stephen J
dc.contributor.editorP.L. Pedersen
dc.date.accessioned2017-05-03T12:22:12Z
dc.date.available2017-05-03T12:22:12Z
dc.date.issued2007
dc.date.modified2010-08-30T07:04:13Z
dc.identifier.issn0145-479X
dc.identifier.doi10.1007/s10863-006-9060-z
dc.identifier.urihttp://hdl.handle.net/10072/18479
dc.description.abstractRecently mitochondria in cancer cells have emerged as the Achilles heel for tumour destruction. Anti-cancer agents specifically targeting cancer cell mitochondria are referred to as 'mitocans'. These compounds act by destabilising these organelles, unleashing their apoptogenic potential, resulting in the efficient death of malignant cells and suppression of tumour growth. Importantly, at least some mitocans are selective for cancer cells, and these are represented by the group of redox-silent vitamin E analogues, epitomised by a-tocopheryl succinate (a-TOS). This compound has proven itself in pre-clinical models to be an efficient anti-cancer agent, targeting complex II of the respiratory chain to displace ubiquinone binding. We propose that disrupting the electron flow of mitochondrial complex II results in generation of superoxide, triggering mitochondrial destabilisation and initiation of apoptotic pathways. Moreover, a-TOS is selective for cancer cells with their reduced anti-oxidant defenses and lower esterase activity than the normal (non-malignant) counterparts. In this mini-review we discuss the emerging significance of mitocans, as exemplified by a-TOS.
dc.description.peerreviewedYes
dc.description.publicationstatusYes
dc.languageEnglish
dc.language.isoeng
dc.publisherSpringer
dc.publisher.placeNew York, USA
dc.relation.ispartofstudentpublicationN
dc.relation.ispartofpagefrom65
dc.relation.ispartofpageto72
dc.relation.ispartofissue1
dc.relation.ispartofjournalJournal of Bioenergetics and Biomembranes
dc.relation.ispartofvolume39
dc.rights.retentionY
dc.subject.fieldofresearchBiochemistry and Cell Biology
dc.subject.fieldofresearchcode0601
dc.titleMitocans as anti-cancer agents targeting mitochondria: lessons from studies with vitamin E analogues, inhibitors of complex II
dc.typeJournal article
dc.type.descriptionC1 - Articles
dc.type.codeC - Journal Articles
gro.date.issued2007
gro.hasfulltextNo Full Text
gro.griffith.authorDyason, Jeffrey C.
gro.griffith.authorNeuzil, Jiri
gro.griffith.authorLambrechts, Ruth M.
gro.griffith.authorRalph, Stephen J.
gro.griffith.authorWang, Xiufang
gro.griffith.authorDong, Lan-feng
gro.griffith.authorProchazka, Lubomir


Files in this item

FilesSizeFormatView

There are no files associated with this item.

This item appears in the following Collection(s)

  • Journal articles
    Contains articles published by Griffith authors in scholarly journals.

Show simple item record